Literature DB >> 29678704

Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.

Daham Kim1, Cheol Ryong Ku2, Se Hee Park1, Ju Hyung Moon3, Eui Hyun Kim3, Sun Ho Kim4, Eun Jig Lee5.   

Abstract

BACKGROUND: It is difficult to distinguish silent corticotroph adenomas (SCAs) from other nonfunctioning pituitary adenomas (NFPAs) preoperatively. This study aimed to determine the preoperative clinical parameters associated with SCAs.
METHODS: This was a retrospective single-center study of patients who underwent surgery for NFPAs during 2011-2016 in our tertiary hospital and who had preoperative combined pituitary function test (CPFT) and immunohistochemical staining results available. After we excluded patients with increased 24-hour urinary free cortisol to preclude overt Cushing's disease, 341 patients were finally enrolled. The medical records, including the CPFT and immunohistochemistry results, of the patients were reviewed.
RESULTS: The age and tumor size were similar between patients with SCAs and other NFPAs. The SCA group had a greater proportion of women (89.2% vs. 57.6%, P < 0.001), cavernous sinus invasion (35.1% vs. 20.7%, P = 0.047), and intratumoral hemorrhage on preoperative sella magnetic resonance imaging (32.4% vs. 9.2%, P < 0.001) compared with the NFPA group. In the preoperative CPFT, the cortisol response was not significantly different between groups. However, the peak adrenocorticotropic hormone (ACTH) (67.80 ± 49.83 vs. 85.67 ± 78.97 pg/mL, P = 0.061) tended to be lower, and the ΔACTH (53.71 ± 50.14 vs. 72.67 ± 75.82 pg/mL, P = 0.046) was significantly lower in SCAs. After we excluded patients with preoperative hypopituitarism caused by mass effects, the peak ACTH (69.39 ± 39.45 vs. 119.75 ± 89.84 pg/mL, P = 0.001) and ΔACTH (58.58 ± 36.51 vs. 107.66 ± 86.05 pg/mL, P = 0.001) were significantly lower in SCAs than in other NFPAs.
CONCLUSIONS: Female sex, cavernous sinus invasion, intratumoral hemorrhage on sella magnetic resonance imaging, and decreased ACTH response in the CPFT are independent indicators of SCAs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACTH; Corticotroph cells; Cushing's disease; Nonfunctioning adenoma; Pituitary adenoma

Mesh:

Substances:

Year:  2018        PMID: 29678704     DOI: 10.1016/j.wneu.2018.04.070

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  7 in total

1.  Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas.

Authors:  Wenting Rui; Nidan Qiao; Yao Zhao; Zhenwei Yao; Yue Wu; Yong Zhang; Ababikere Aili; Zhaoyun Zhang; Hongying Ye; Yongfei Wang
Journal:  Eur Radiol       Date:  2021-11-27       Impact factor: 7.034

Review 2.  Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.

Authors:  José Miguel Hinojosa-Amaya; César Ernesto Lam-Chung; Daniel Cuevas-Ramos
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

3.  Editorial Comment: Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas.

Authors:  Vincent Bourbonne
Journal:  Eur Radiol       Date:  2022-01-19       Impact factor: 5.315

4.  Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.

Authors:  Keyi Zhang; Xuefei Shou; Hong Chen; Nidan Qiao; Wenqiang He; Zhengyuan Chen; Ming Shen; Shiqi Li; Yao Zhao; Zhaoyun Zhang; Yiming Li; Hongying Ye; Yongfei Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-18       Impact factor: 5.555

Review 5.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

6.  A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors.

Authors:  Abhijit Goyal-Honavar; Sauradeep Sarkar; H S Asha; Nitin Kapoor; Rajesh Balakrishnan; Harshad Vanjare; Geeta Chacko; Ari G Chacko
Journal:  Acta Neurochir (Wien)       Date:  2021-06-28       Impact factor: 2.216

7.  Postoperative expression of Cushing disease in a young male: metamorphosis of silent corticotroph adenoma?

Authors:  Sharmin Jahan; M A Hasanat; Tahseen Mahmood; Shahed Morshed; Raziul Haq; Md Fariduddin
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.